UNSPSC 51172132: Moxaverine or moxaverine hydrochloride

This classification denotes an antispasmotic agent with the molecular formulas C20H21NO2 and C20H21NO2.ClH, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers P3P08Y1XJ4, chemically known as 3-ethyl-1-benzyl-6,7-dimethoxyisoquinoline but generally known as moxaverine, which bears US NIH Compound Identifier 70882. European Medicines Agency schedules Moxaverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB09082MIG and SUB03341MIG.

UNSPSC 51172132 Moxaverine or moxaverine hydrochloride is a Commodity code that does not align with recent state and local procurement activity. The single recent opportunity posted under this code—Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing services—concerns laboratory testing infrastructure, staffing, and immunoassay / confirmatory testing methodologies (LC/MS/MS, GC/MS, oral fluid, and hair testing), not procurement of moxaverine or moxaverine hydrochloride as a pharmaceutical or chemical reagent. The scope includes operation of two collection sites in Plano and McKinney, management of randomized testing notifications, and electronic result reporting, with annual testing demand estimated at approximately 25,031 tests across five-panel and six-panel screening panels and ancillary testing.

The Collin County opportunity (RFP 2026-327, due July 23, 2026, estimated contract value $600,000) represents the only recent state and local solicitation associated with this code in the source data. The contract runs two years commencing September 1, 2026, with three optional one-year renewals, and requires the successful vendor to maintain lab certification from SAMHSA, TX DPS, or CAP. Pricing is on a per-test basis across three service models (screening only, confirmation after screening, and screening with automatic confirmation of positives), with price redetermination limited to annual September 1 anniversaries based on medical Consumer Price Index increases not exceeding 3.0 percent. The mismatch between the code's nominal scope and the actual work being solicited suggests this code carries minimal relevant recent activity for vendors in the pharmaceutical or chemical reagent space.